Risk of severe respiratory syncytial virus disease, identification of high risk infants and recommendations for prophylaxis with palivizumab.
Meissner
H Cody
HC
Rennels
Margaret B
MB
Pickering
Larry K
LK
Hall
Caroline B
CB
D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents / Q000008:administration & dosage; D004334:Drug Administration Schedule; D006760:Hospitalization / Q000706:statistics & numerical data / Q000639:trends; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature; D007363:Intensive Care Units, Neonatal; D000069455:Palivizumab; D017410:Practice Guidelines as Topic; D011322:Primary Prevention / Q000379:methods; D018357:Respiratory Syncytial Virus Infections / Q000188:drug therapy / Q000517:prevention & control*; D018570:Risk Assessment
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000998:Antiviral Agents; D000069455:Palivizumab